FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2047367159> ?p ?o ?g. }

• W2047367159 abstract "Terazosin is an alpha1-selective adrenoceptor blocking agent that has been reported in many clinical trials to be an effective choice for the treatment of benign prostatic hyperplasia (BPH). To improve cost-effectiveness, the development of an effective and well-tolerated generic formulation is needed.The aim of this study was to compare the efficacy and tolerability of branded versus generic terazosin hydrochloride in adult patients with symptomatic BPH in Taiwan.This randomized, open-label, 2-sequence, 2-period crossover study was conducted at the Urological Clinic, National Cheng Kung University Medical Center, Taman, Taiwan. Men newly diagnosed with symptomatic BPH who had not previously received treatment for BPH were recruited between August 2002 and April 2006. Patients were randomly assigned to 1 of 2 treatment sequences. Group A received generic terazosin during period 1 (6 weeks) and branded terazosin in period 2 (6 weeks); group B received the branded drug during period 1 and the generic during period 2. The 2 study periods were separated by a 1-week washout period. All treatments were given by mouth once daily (bedtime) at an initial dosage of 2 mg/d for the first 2 weeks. At the week-2 study visit in each treatment period, the dosage could be increased to 4 mg/d or decreased to 1 mg/d based on each patient's response and experience of adverse effects (AEs), based on the opinion of the investigator. Efficacy variables included the total score on the International Prostate Symptom Scale (IPSS), a 7-item instrument used to assess objective lower urinary tract symptoms, including quality of life. IPSS was measured at baseline and weeks 2 and 6 of each treatment period, and maximal and mean uroflow rates, measured at baseline and week 6. Tolerability was assessed at each time point using physical examination, including vital signs; laboratory analysis; and spontaneous reporting.Fifty-three patients were randomized; 43 were included in the efficacy analysis (mean [SD] age, group A, 64.5 [7.7] years and group B, 62.9 [8.2] years; mean [SD] weight, group A, 66.4 [7.2] kg and group B, 67.1 [8.9] kg; all patients were Taiwanese). At 2 and 6 weeks, no significant between-product differences were found in mean (SD) decreases from baseline in IPSS total score (generic, 2.46 [0.84] and 2.46 [1.00], respectively; branded, 1.56 [0.60] and 2.87 [0.71]). At week 6, the between-product difference in mean increase from baseline in maximal uroflow rate was nonsignificant (generic, 2.36 [0.90] mL/s; branded, 2.03 [0.62] mL/s). A total of 86 treatment-emergent AEs were reported (45 with the generic drug; 41 with the branded drug), all of which were considered by the investigator as nonserious except for 1 case of acute epididymitis, which occurred with the generic drug. The most common AEs reported with the generic and branded formulations were dizziness (7/48 [14.6%] and 10/50 [20.0%], respectively) and peripheral edema (1/48 [2.1%] and 3/50 [6.0%]). No significant differences in the prevalences of AEs were found between the 2 treatments.In this group of Taiwanese patients with symptomatic BPH, the efficacy and tolerability of generic terazosin were similar to those of branded terazosin." @default.
• W2047367159 created "2016-06-24" @default.
• W2047367159 creator A5008237683 @default.
• W2047367159 creator A5010238653 @default.
• W2047367159 creator A5027236203 @default.
• W2047367159 creator A5069389983 @default.
• W2047367159 date "2007-04-01" @default.
• W2047367159 modified "2023-09-25" @default.
• W2047367159 title "Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: A randomized, open-label, crossover study in taiwan" @default.
• W2047367159 cites W1966862172 @default.
• W2047367159 cites W1988883837 @default.
• W2047367159 cites W2005166051 @default.
• W2047367159 cites W2012695517 @default.
• W2047367159 cites W2037698344 @default.
• W2047367159 cites W2058720768 @default.
• W2047367159 cites W2073123650 @default.
• W2047367159 cites W2081313560 @default.
• W2047367159 cites W2104580244 @default.
• W2047367159 cites W2139651041 @default.
• W2047367159 cites W2151504928 @default.
• W2047367159 cites W2249623265 @default.
• W2047367159 cites W2413300521 @default.
• W2047367159 cites W2418950777 @default.
• W2047367159 cites W2419306660 @default.
• W2047367159 doi "https://doi.org/10.1016/j.clinthera.2007.04.013" @default.
• W2047367159 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17617290" @default.
• W2047367159 hasPublicationYear "2007" @default.
• W2047367159 type Work @default.
• W2047367159 sameAs 2047367159 @default.
• W2047367159 citedByCount "4" @default.
• W2047367159 countsByYear W20473671592015 @default.
• W2047367159 countsByYear W20473671592021 @default.
• W2047367159 crossrefType "journal-article" @default.
• W2047367159 hasAuthorship W2047367159A5008237683 @default.
• W2047367159 hasAuthorship W2047367159A5010238653 @default.
• W2047367159 hasAuthorship W2047367159A5027236203 @default.
• W2047367159 hasAuthorship W2047367159A5069389983 @default.
• W2047367159 hasConcept C121608353 @default.
• W2047367159 hasConcept C126322002 @default.
• W2047367159 hasConcept C126894567 @default.
• W2047367159 hasConcept C142724271 @default.
• W2047367159 hasConcept C168563851 @default.
• W2047367159 hasConcept C197934379 @default.
• W2047367159 hasConcept C204787440 @default.
• W2047367159 hasConcept C27081682 @default.
• W2047367159 hasConcept C2776235491 @default.
• W2047367159 hasConcept C2776679619 @default.
• W2047367159 hasConcept C2777562237 @default.
• W2047367159 hasConcept C2778375690 @default.
• W2047367159 hasConcept C2778537899 @default.
• W2047367159 hasConcept C2779384505 @default.
• W2047367159 hasConcept C71924100 @default.
• W2047367159 hasConcept C87813604 @default.
• W2047367159 hasConceptScore W2047367159C121608353 @default.
• W2047367159 hasConceptScore W2047367159C126322002 @default.
• W2047367159 hasConceptScore W2047367159C126894567 @default.
• W2047367159 hasConceptScore W2047367159C142724271 @default.
• W2047367159 hasConceptScore W2047367159C168563851 @default.
• W2047367159 hasConceptScore W2047367159C197934379 @default.
• W2047367159 hasConceptScore W2047367159C204787440 @default.
• W2047367159 hasConceptScore W2047367159C27081682 @default.
• W2047367159 hasConceptScore W2047367159C2776235491 @default.
• W2047367159 hasConceptScore W2047367159C2776679619 @default.
• W2047367159 hasConceptScore W2047367159C2777562237 @default.
• W2047367159 hasConceptScore W2047367159C2778375690 @default.
• W2047367159 hasConceptScore W2047367159C2778537899 @default.
• W2047367159 hasConceptScore W2047367159C2779384505 @default.
• W2047367159 hasConceptScore W2047367159C71924100 @default.
• W2047367159 hasConceptScore W2047367159C87813604 @default.
• W2047367159 hasLocation W20473671591 @default.
• W2047367159 hasLocation W20473671592 @default.
• W2047367159 hasOpenAccess W2047367159 @default.
• W2047367159 hasPrimaryLocation W20473671591 @default.
• W2047367159 hasRelatedWork W157089611 @default.
• W2047367159 hasRelatedWork W1975274241 @default.
• W2047367159 hasRelatedWork W2047367159 @default.
• W2047367159 hasRelatedWork W2053978887 @default.
• W2047367159 hasRelatedWork W2059312266 @default.
• W2047367159 hasRelatedWork W2168585646 @default.
• W2047367159 hasRelatedWork W2372975949 @default.
• W2047367159 hasRelatedWork W2922533892 @default.
• W2047367159 hasRelatedWork W2981759451 @default.
• W2047367159 hasRelatedWork W2399450262 @default.
• W2047367159 isParatext "false" @default.
• W2047367159 isRetracted "false" @default.
• W2047367159 magId "2047367159" @default.
• W2047367159 workType "article" @default.